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ABSTRACT
The resistance to chemotherapy and the tumor escape from host immunosurveillance 
are the main causes of the failure of anthracycline-based regimens in breast cancer, 
where an effective chemo-immunosensitizing strategy is lacking. 
The clinically used aminobisphosphonate zoledronic acid (ZA) reverses 
chemoresistance and immunoresistance in vitro. Previously we developed a 
nanoparticle-based zoledronic acid-containing formulation (NZ) that allowed a higher 
intratumor delivery of the drug compared with free ZA in vivo. We tested its efficacy 
in combination with doxorubicin in breast tumors refractory to chemotherapy and 
immune system recognition as a new combinatorial approach to produce chemo- and 
immunosensitization.
NZ reduced the IC50 of doxorubicin in human and murine chemoresistant breast 
cancer cells and restored the doxorubicin efficacy against chemo-immunoresistant 
tumors implanted in immunocompetent mice. By reducing the metabolic flux through 
the mevalonate pathway, NZ lowered the activity of Ras/ERK1/2/HIF-1α axis and 
the expression of P-glycoprotein, decreased the glycolysis and the mitochondrial 
respiratory chain, induced a cytochrome c/caspase 9/caspase 3-dependent apoptosis, 
thus restoring the direct cytotoxic effects of doxorubicin on tumor cell. Moreover, NZ 
restored the doxorubicin-induced immunogenic cell death and reversed the tumor-
induced immunosuppression due to the production of kynurenine, by inhibiting the 
STAT3/indoleamine 2,3 dioxygenase axis. These events increased the number of 
dendritic cells and decreased the number of immunosuppressive T-regulatory cells 
infiltrating the tumors. 
Our work proposes the use of nanoparticle encapsulating zoledronic acid as an 
effective tool overcoming at the same time chemoresistance and immunoresistance 
in breast tumors, thanks to the effects exerted on tumor cell and tumor-infiltrating 
immune cells.
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INTRODUCTION
Anthracycline-based regimens are widely used as 
neo-adjuvant and adjuvant chemotherapy against breast 
cancers [1, 2]. The main drawbacks of anthracyclines 
like doxorubicin are the onset of cardiotoxicity [3, 4] and 
the onset of drug resistance that makes chemotherapy 
progressively ineffective. Doxorubicin, as well as the other 
anthracyclines, are substrates of ATP binding cassette 
(ABC) transporters, such as P-glycoprotein (Pgp) and 
multidrug resistance related protein 1 (MRP1), which 
efflux the drugs outside the tumor cell, thus lowering their 
cytotoxicity [5].
Liposomal doxorubicin has been successfully 
employed to circumvent cardiotoxicity [6], but it is not 
effective against doxorubicin-resistant breast tumors 
[7]. The co-administration of chemosensitizing agents, 
such as ABC transporter inhibitors of natural or synthetic 
origin, has obtained promising results in vitro [8–11]. This 
approach, however, failed to overcome drug resistance 
in vivo, for the low specificity and high toxicity of the 
chemosensitizing agents [10, 12].
A second criticism of doxorubicin-resistant tumors 
is their simultaneous resistance to chemotherapy and 
immune system. In drug-sensitive tumors, doxorubicin 
induces an immunogenic cell death, by promoting the 
plasma membrane exposure of the protein calreticulin 
(CRT), which activates the local dendritic cells (DCs) to 
phagocytize tumor cells and stimulates the subsequent 
expansion of anti-tumor CD8+ T-lymphocytes [13]. 
These mechanisms work in doxorubicin-sensitive tumors, 
not in doxorubicin-resistant ones: here Pgp hinders the 
doxorubicin-mediated immunogenic cell death by rapidly 
effluxing the drug and by inhibiting the immunosensitizing 
function of CRT [14, 15]. Besides escaping the DC-
mediated immunosurveillance, drug-resistant tumors 
show also highly basal synthesis of kynurenine [16, 17], 
an immunosuppressive catabolite of tryptophan that is 
produced by indoleamine 2,3-dioxygenase (IDO) [18]. 
Kynurenine reduces the proliferation and survival of CD4+ 
and CD8+ T-lymphocytes [17], and promotes the expansion 
of the immunosuppressive T-regulatory (Treg) cells [16], 
favoring the immunoescape of drug-resistant tumors.
Since an active immune system plays an important 
role in limiting the growth and relapse of breast tumors 
[19–21], chemo-immunotherapy-based approaches are 
under intensive investigation for these cancers [22–24]. 
An “ideal” doxorubicin-based regimen for breast cancer 
should circumvent the tumor drug resistance and prevent 
at the same time the tumor-induced immunoresistance and 
immunosuppression. 
We previously demonstrated that zoledronic acid 
(ZA), a clinically used aminobisphosphonate that inhibits 
the farnesyl pyrophosphate synthase (FPPS) step in 
the mevalonate pathway [25], is an effective chemo-
immunosensitizing agent in doxorubicin-resistant cell lines 
in vitro [16, 26]. When administered as free agent, however, 
ZA is avidly taken by bone and reaches insufficient intra-
tumor concentrations [27]. To overcome this criticism we 
developed self-assembling nanoparticles (NPs) encapsulating 
ZA (here called NZ): compared to free ZA, NZ exhibited 
increased intra-tumor delivery of the aminobisphosphonate 
[28, 29] and increased anti-proliferative effects against 
tumors implanted in immunodeficient animals [30–33]. 
Moreover, the self-assembling feature of these NPs makes 
them suitable for clinical applications, overcoming the issues 
generally associated with the scale-up and clinical use of NP 
formulations [28].
In this work, we investigated whether NZ - in 
combination with doxorubicin - overcomes chemoresistance 
and immunoresistance of breast tumors implanted in 
immunocompetent mice, rescuing the anthracycline’s 
efficacy in refractory breast cancers. 
RESULTS
NZ reduces the resistance to doxorubicin 
in breast cancer cells and the growth of 
chemoresistant tumors
We first tested the chemosensitizing effects of NZ 
and free ZA in a panel of human and murine breast cancer 
cell lines, showing different expression of the doxorubicin 
efflux transporters Pgp and MRP1 (Figure 1A). NZ and 
ZA increased the doxorubicin intracellular retention 
(Figure 1B) and lowered the doxorubicin IC50 (Figure 1C), 
according to the number of viable cells positive for the 
neutral red staining after 72 h of treatment: these effects 
were specific for tumor cells, since they did not occur in 
the non-transformed MCF10A epithelial cells. NZ was 
as effective as ZA in the cell lines with low Pgp levels 
(i.e. MCF7, SKBR3, T74D cells) and significantly more 
effective than ZA in the cell lines with high Pgp levels (i.e. 
MDA-MB-231, JC, TUBO cells), suggesting that it was an 
effective chemosensitizing agent in doxorubicin-resistant 
breast cancer cells.
In the subsequent set of experiments, we focused on 
the JC model, a constitutively doxorubicin-resistant cell 
line over-expressing Pgp and syngeneic with BALB/c mice 
[34]. JC cells stably transduced with a luciferase expression 
vector (JC-luc clone) were implanted in immunocompetent 
animals. As shown by the in vivo bioluminescence imaging 
(Figure 2A–2B), by the manual measurement of tumor 
growth (Figure 2C) and by the tumor gross pathology 
(Figure 2D and Table 1), doxorubicin and ZA alone did 
not reduce tumor progression. The combination of ZA 
and doxorubicin, as well as NZ alone, produced a small 
reduction of tumor growth (Figure 2A–2D and Table 1) 
and decreased tumor cell proliferation, as revealed by 
the Ki67 staining (Figure 2E). The association of NZ 
and doxorubicin had the strongest effects on the tumor 
growth (Figure 2A–2D and Table 1); such association 
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reduced tumor cellularity and proliferation, and induced the 
appearance of intra-tumor necrotic areas (Figure 2E). This 
combination did not induce more damage on liver, heart and 
kidney compared to the other treatments, as suggested by 
the hematochemical parameters of hepatotoxicity (lactate 
dehydrogenase LDH, aspartate aminotransferase AST, 
alanine aminotransferase ALT, alkaline phosphatase AP), 
cardiotoxicity (creatine phosphokinase CPK), nefrotoxicity 
(creatinine; Table 2). NPs without ZA (blank NPs) did not 
exert any chemosensitizing effects in vitro (Supplementary 
Figure 1A–1B) and in vivo (Supplementary Figure 1C), and 
were not further evaluated in the study.
NZ lowers the Pgp levels in chemoresistant 
tumors
Since the chemosensitizing effects were more related 
to the presence of Pgp than MRP1, which was present in 
only two of Pgp-containing cell lines and was less expressed 
than Pgp, we focused our attention on the modulation of 
the latter. In line with recent findings on lung cancer [33], 
NZ and - at a lesser extent ZA - lowered the activity of Ras 
and Ras-downstream effectors ERK1/2 (Figure 3A), the 
amount, phosphorylation, nuclear translocation (Figure 3B) 
and activity (Figure 3C) of HIF-1α, the transcription of the 
HIF-1α-target gene Pgp (Figure 3D) and the amount of Pgp 
protein (Figure 3E) in JC tumor extracts. The effects of NZ 
on Ras/ERK1/2/HIF-1α/Pgp axis was likely due to the strong 
reduction in the synthesis of FPP (Supplementary Figure 2), a 
critical metabolite for Ras activity [35]. ZA caused a significant 
but weaker decrease in FPP levels (Supplementary Figure 2); 
doxorubicin did not alter FPP synthesis (Supplementary 
Figure 2) or Ras/ERK1/2 activity in untreated, ZA-treated and 
NZ-treated tumors (Figure 3A). The anthracycline increased 
HIF-1α amount and nuclear translocation, (Figure 3B–3C) and 
Pgp levels (Figure 3D) in tumor extracts: these effects were 
fully prevented by NZ, which decreased HIF-1α and Pgp 
amount below the control (Figure 3B–3E).
Figure 1: NZ reverses doxorubicin resistance in breast cancer cells. Human non transformed breast epithelial MCF10A cells, 
human breast cancer MCF7, SKBR3, T74D, MDA-MB-231 cells, murine mammary cancer TUBO and JC cells were subjected to the 
following investigations. (A) Western blot analysis of Pgp and MRP1. The actin expression was used as control of equal protein loading. 
The figure is representative of 3 experiments with similar results. (B) Cells were incubated for 24 h with 5 µmol/L doxorubicin (Dox), 
1 µmol/L zoledronic acid (ZA) for 24 h followed by 5 µmol/L doxorubicin for additional 24 h (ZA + Dox), 1 µmol/L self-assembling ZA 
formulation (NZ) for 24 h followed by 5 µmol/L doxorubicin for additional 24 h (NZ + Dox). The intracellular content of doxorubicin 
was measured spectrofluorimetrically in duplicate (n = 4). Data are presented as means ± SD. Versus Dox: *p < 0.001; NZ + Dox versus 
ZA + Dox: °p < 0.01. (C) Cells were left untreated or incubated for 72 h in the presence of 1 µmol/L ZA or NZ; different concentrations 
(1 nmol/L, 10 nmol/L, 100 nmol/L, 1 µmol/L, 10 µmol/L, 100 µmol/L, 1 mmol/L) of doxorubicin (Dox) were added in the last 48 h. Sample 
were then stained in quadruplicate with the neutral red solution (n = 4). IC50 was calculated as the concentration of doxorubicin that kills 
50% of cells. Data are presented as means ± SD. Versus Dox: *p < 0.05; NZ + Dox versus ZA + Dox: °p < 0.005.
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NZ impairs the energy metabolism and the 
mitochondrial functions, inducing cytochrome 
c/caspase 9/caspase 3-dependent apoptosis in 
chemoresistant tumors 
Doxorubicin increased the mRNA levels of the 
HIF-1α-target genes involved in the glucose uptake and 
glycolytic flux, such as glucose transporter 1 (GLUT1), 
hexokinase (HK), phosphofructokinase-1 (PFK1), 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
enolase A (ENOA), pyruvate kinase (PK) in tumor 
extracts (Figure 4A). By contrast, NZ, either alone or 
in the presence of doxorubicin, significantly reduced 
the levels of these mRNAs in JC tumors (Figure 4A). In 
keeping with these effects, doxorubicin increased and NZ 
decreased the glucose uptake (Figure 4B) and the glucose 
flux through glycolysis and tricarboxylic acid (TCA) cycle 
(Figure 4C) in JC cells. 
Figure 2: The association of NZ and doxorubicin reduces the growth of chemoresistant tumors. Six weeks-old female 
BALB/c mice bearing 60 mm3 JC-luc tumors were randomly divided into the following groups (10 mice/group): 1) Ctrl group, treated with 
0.1 mL saline solution i.v. at day 3, 9, 15; 2) Dox group, treated with 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 3) ZA group, treated with 
20 µg/mouse ZA i.v. at day 2, 8, 14; 4) ZA + Dox group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14 followed by 5 mg/kg doxorubicin 
i.v. at day 3, 9, 15; 5) NZ group, treated with 20 µg/mouse self-assembling ZA formulation i.v. at day 2, 8, 14; 6) NZ + Dox group, treated 
with 20 µg/mouse NZ i.v. at day 2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at day 3, 9, 15. (A) Representative in vivo bioluminescence 
imaging, performed at day 0, 6, 12, 18 after randomization. (B) Photons quantification of tumors according to the imaging data. Data are 
presented as means ± SD. Versus Ctrl group: *p < 0.01. (C) Tumor growth was monitored daily by caliper measurement. Data are presented 
as means ± SD. Versus Ctrl group: *p < 0.005. (D) Photograph of representative tumors from each treatment group after mice sacrifice. 
(E) Sections of tumors from each group of animals were stained with hematoxylin and eosin (HE; upper panel: 20× objective; lower 
panel: 63× objective; stars: necrotic areas) or immunostained for Ki67 (63× objective). Nuclei were counter-stained with hematoxylin. 
Bar = 10 µm. The photographs are representative of sections from 5 tumors/group. The percentage of proliferating cells was determined 
by the ratio of Ki67-positive nuclei and the total nuclei (hematoxylin-positive nuclei), by counting sections from 5 animals of each group 
(108–73 nuclei/field). Ctrl group percentage was considered 100%. Data are presented as means + SD. Versus Ctrl group: *p < 0.05; versus 
Dox group: °p < 0.002.
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Whereas doxorubicin had no effect on mitochondrial 
electron flux (Figure 5A) and ATP production (Figure 5B), 
NZ decreased these parameters (Figure 5A–5B). 
NZ effect was likely due to the decreased amount of 
the mitochondrial electron transporter ubiquinone 
(Supplementary Figure 3), whose synthesis depends on 
the mevalonate pathway, since it contains an isoprenoid 
tail essential for its activity [36]. The impairment of the 
mitochondrial energy metabolism induced by NZ was 
paralleled by increased reactive oxygen species (ROS; 
Figure 5C), mitochondrial depolarization (Figure 5D), 
release of cytochrome c in the cytosol (Figure 5E), 
activation of caspase 9 and caspase 3 (Figure 5F). 
ZA, which decreased the energy metabolism (Figure 4, 
Figure 5A–5B) and ubiquinone synthesis (Supplementary 
Figure 3) less than NZ, poorly increased ROS levels and 
mitochondrial depolarization, without eliciting cytochrome 
c release and caspases activation (Figure 5C–5F). Similarly, 
doxorubicin was devoid of any mitochondrial-damaging 
or pro-apoptotic effects in JC cells. Only the pre-treatment 
with NZ induced all these events in doxorubicin-treated cells 
(Figure 5C–5F). The activation of caspase 9 and caspase 3 by 
NZ was time-dependent (Supplementary Figure 4A–4D); the 
addition of doxorubicin further increased caspases activities 
in cells incubated with NZ for at least 12 h (Supplementary 
Figure 4A–4D; Figure 5F).
The association of NZ and doxorubicin restores 
the recognition of resistant tumors by the host 
immune system
We previously demonstrated that the combination of 
ZA and doxorubicin restored the immunogenic effects of 
the anthracycline in mildly chemoresistant cells in vitro, 
where doxorubicin alone was ineffective [26]. However, 
in the highly chemoresistant JC cells, the association of 
doxorubicin and ZA elicited low pro-immunogenic effects, 
as revealed by the very weak extracellular release of ATP 
(Figure 6A) and high mobility group binding protein 1 
(HMGB1; Figure 6B–6C), and by the absence of CRT 
exposure on JC cell surface (Figure 6D), considered as 
indexes of immunogenic death [37]. ZA and NZ alone 
did not elicit these effects as well. Interestingly, the 
association of NZ and doxorubicin was the only treatment 
that significantly increased the extracellular release of ATP 
and HMGB1 (Figure 6A–6C), and the exposure of CRT 
Table 1: Measurement of animals weight, tumor weight and tumor growth inhibition
 Ctrl Dox ZA ZA + dox NZ NZ + dox
Final mice weight (g) 20.28 ± 3.46 20.19 ± 3.81 21.09 ± 2.33 20.11 ± 1.29 20.01 ± 2.74 19.68 ± 1.82
Final tumor weight (g) 3.51 ± 0.72 3.18 ± 0.91 3.02 ± 0.39 2.28 ± 0.31* 2.25 ± 0.42* 1.12 ± 0.24*
% inhibition rate 9.40% 13.96% 35.04%* 35.90%* 68.09%*
Animals (n = 10/group) were treated as reported under Materials and methods. The percentage of inhibition rate was calculated 
as it follows: (average tumor weight of control group – average tumor weight of test group)/average tumor weight of control 
group × 100%. Significance versus Ctrl group: *p < 0.01.
Table 2: Hematochemical parameters of animals
 Ctrl Dox ZA ZA + Dox NZ NZ + Dox
LDH (U/L) 6052 ± 1761 7098 ± 1872 6677 ± 1512 7551 ± 1927 7091 ± 1872 7381 ± 1724
AST (U/L) 235 ± 81 289 ± 77 322 ± 81 331 ± 67 284 ± 62 312 ± 86
ALT (U/L) 27.5 ± 4.5 29.8 ± 6.3 28.6 ± 1.9 30.6 ± 3.4 28.7 ± 3.4 28.6 ± 3.4
AP (U/L) 81 ± 16 74 ± 11 79 ± 11 81 ± 18 82 ± 13 79 ± 13
CPK (U/L) 467 ± 109 670 ± 156 681 ± 208 608 ± 192 679 ± 129 689 ± 132
Creatinine 
(mg/L) 0.034 + 0.004 0.036 ± 0.005 0.038 ± 0.004 0.040 ± 0.005 0.039 ± 0.004 0.037 ± 0.007
Animals (n = 10/group) were treated as reported under Materials and methods. Blood was collected immediately after mice 
euthanasia and analyzed for lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (AP), creatine phosphokinase (CPK), creatinine. There were not statistically significant differences 
among each group of treatment.
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Figure 3: NZ decreases the activation of Ras/ERK1/2/HIF1α axis and the expression of Pgp in chemoresistant tumors. 
Six weeks-old female BALB/c mice bearing 60 mm3 JC-luc tumors were randomly divided into the following groups (10 mice/group): 
1) Ctrl group, treated with 0.1 mL saline solution i.v. at day 3, 9, 15; 2) Dox group, treated with 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 
3) ZA group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14; 4) ZA + Dox group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14 followed 
by 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 5) NZ group, treated with 20 µg/mouse self-assembling ZA formulation i.v. at day 2, 8, 14; 
6) NZ + Dox group, treated with 20 µg/mouse NZ i.v. at day 2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at day 3, 9, 15. (A) Tumor 
extracts were subjected to the Western blot analysis for Ras-GTP, total Ras, phospho(Thr202/Tyr204, Thr185/Tyr187)-ERK1/2, total 
ERK1/2. The actin expression was used as control of equal protein loading. The figure is representative of 4 tumors per each group. 
(B) Cytosolic (CYT) and nuclear (NCL) fractions were separated from tumor extracts and analyzed for the expression of phospho(Ser)
HIF-1α and HIF-1α by Western blotting. The actin and TBP expressions were used as controls of equal protein loading in each fraction. The 
figure is representative of 4 tumors per each group. (C) HIF-1α activity was measured in nuclear extracts from each tumor (n = 10/group) by 
ELISA. Data are presented as means + SD. Versus Ctrl group: *p < 0.05; versus Dox group: °p < 0.05. (D) Pgp mRNA levels were detected 
in each tumor extract (n = 10/group) by qRT-PCR. Data are presented as means + SD. Versus Ctrl group: *p < 0.05; versus Dox group: 
°p < 0.01. (E) Sections of tumors from each group of animals were immunostained for Pgp. Nuclei were counter-stained with hematoxylin. 
Bar = 10 µm (63× objective). The photographs are representative of sections from 5 tumors/group. The percentage of Pgp-positive cells was 
determined by analyzing sections from 5 animals of each group (110–72 cells/field), using Photoshop program. The intensity of Ctrl group 
was considered 100%. Data are presented as means + SD. Versus Ctrl group: *p < 0.05; versus Dox group: °p < 0.001. 
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on JC cell surface (Figure 6D). NZ increased the release 
of ATP and HMGB1 if incubated at least 48 h before 
doxorubicin; shorter incubations did not elicited these 
effects (Supplementary Figure 5A–5H).
In keeping with these findings, the number of cells 
positive for CRT and the number of DCs present within 
JC tumors, revealed by the staining for the DC-marker 
CD11c, were markedly increased in animals exposed to 
NZ and doxorubicin (Figure 6E). 
NZ lowers the tumor-induced kynurenine 
production by reducing the activation of STAT3 
and decreases the number of intra-tumor Treg 
lymphocytes
As observed previously, ZA can lower in vitro 
the synthesis of the immunosuppressive metabolite 
kynurenine, by inhibiting the Ras/ERK1/2 pathway and the 
phosphorylation of STAT3 on serine 727 [16]. In JC tumors 
Figure 4: NZ reduces the glucose metabolism in chemoresistant cells. (A) Six weeks-old female BALB/c mice bearing 60 mm3 
JC-luc tumors were randomly divided into the following groups (10 mice/group): 1) Ctrl group, treated with 0.1 mL saline solution i.v. at 
day 3, 9, 15; 2) Dox group, treated with 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 3) ZA group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 
14; 4) ZA + Dox group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 5) NZ group, 
treated with 20 µg/mouse self-assembling ZA formulation i.v. at day 2, 8, 14; 6) NZ + Dox group, treated with 20 µg/mouse NZ i.v. at day 
2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at day 3, 9, 15. Tumor extracts (n = 10/group) were analyzed for the mRNA levels of GLUT1, 
HK, PFK1, GAPDH, ENOA, PK by qRT-PCR. Data are presented as means + SD. Versus Ctrl group: *p < 0.001; versus Dox group: 
°p < 0.001. (B) JC cells were grown in fresh medium (Ctrl) or medium containing 5 µmol/L doxorubicin (Dox, 24 h), 1 µmol/L zoledronic 
acid (ZA, 48 h), 1 µmol/L ZA for 24 h followed by 5 µmol/L doxorubicin for additional 24 h (ZA + Dox), 1 µmol/L self-assembling ZA 
formulation (NZ, 48 h), 1 µmol/L NZ for 24 h followed by 5 µmol/L doxorubicin for additional 24 h (NZ + Dox). The uptake of 2-deoxy-
D-[3H]-glucose was measured by cell radiolabeling and quantified by liquid scintillation. Data are presented as means + SD (n = 3). Versus 
Ctrl: *p < 0.001; versus Dox: °p < 0.002. (C) JC cells were incubated as reported in (B). The glucose flux through glycolysis and TCA 
cycle was measured in cells radiolabeled with [6–14C]-glucose. Data are presented as means + SD (n = 3). Versus Ctrl: *p < 0.001; versus 
Dox: °p < 0.001.
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extracted from mice treated with ZA, however, we did not 
observe any reduction of phosphorylated STAT3 (Figure 7A), 
IDO mRNA (Figure 7B) and kynurenine production 
(Figure 7C). These three events were instead detected 
in tumors derived from NZ-treated animals and were not 
affected by doxorubicin (Figure 7A–7C). Neither ZA nor 
NZ, alone and in combination with doxorubicin, modified 
the amount of intra-tumor CD19+, CD4+ or CD8+ cells 
(Supplementary Figure 6), suggesting that they did not 
affect the amount of B- and T-lymphocytes infiltrating the 
tumor bulk.
High levels of kynurenine have been correlated with 
the expansion of immunosuppressive Treg cells [16], which 
favor an immunotolerant and permissive environment 
Figure 5: NZ impairs the mitochondrial metabolism and induces apoptotic death in chemoresistant cells. JC cells were 
grown in fresh medium (Ctrl) or medium containing 5 µmol/L doxorubicin (Dox, 24 h), 1 µmol/L zoledronic acid (ZA, 48 h), 1 µmol/L 
ZA for 24 h followed by 5 µmol/L doxorubicin for additional 24 h (ZA + Dox), 1 µmol/L self-assembling ZA formulation (NZ, 48 h), 
1 µmol/L NZ for 24 h followed by 5 µmol/L doxorubicin for additional 24 h (NZ + Dox). (A) The electron flux between Complex I and 
III, either ubiquinone-independent (i.e. in the absence of the Complex I inhibitor rotenone, 50 µmol/L) or ubiquinone-dependent (i.e. in the 
presence of rotenone), was measured spectrophotometrically in isolated mitochondria. Data are presented as means + SD (n = 3). Versus 
Ctrl: *p < 0.05; versus Dox: °p < 0.01. (B) ATP levels in isolated mitochondria were measured by a chemiluminescence-based assay. Data 
are presented as means + SD (n = 3). Versus Ctrl: *p < 0.01; versus Dox: °p < 0.01. (C) Intramitochondrial ROS levels were measured 
spectrofluorimetrically in triplicate using the DCFDA-AM probe. Data are presented as means + SD (n = 3). Versus Ctrl: *p < 0.05; versus 
Dox: °p < 0.001. (D) The mitochondrial membrane potential was assessed by the JC-1 staining method. The percentage of green versus 
red mitochondria was considered an index of mitochondrial depolarization and permeability transition. Data are presented as means + SD 
(n = 3). Versus Ctrl: *p < 0.05; versus Dox: °p < 0.001. (E) Mitochondrial (MIT) and cytosolic (CYT) extracts were analyzed for the levels 
of cytochrome c by Western blotting. The porin and actin expressions were used as controls of equal protein loading in each fraction. The 
figure is representative of 3 experiments. (F) The activities of caspase 9 and 3 were measured spectrofluorimetrically in the cell lysates. 
Data are presented as means + SD (n = 3). Versus Ctrl: *p < 0.005; versus Dox: °p < 0.005. 
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Figure 6: NZ restores the doxorubicin-induced immunogenic death in chemoresistant tumors. (A) JC cells were grown 
in fresh medium (Ctrl) or medium containing 5 µmol/L doxorubicin (Dox, 24 h), 1 µmol/L zoledronic acid (ZA, 48 h), 1 µmol/L ZA for 
24 h followed by 5 µmol/L doxorubicin for additional 24 h (ZA + Dox), 1 µmol/L self-assembling ZA formulation (NZ, 48 h), 1 µmol/L 
NZ for 24 h followed by 5 µmol/L doxorubicin for additional 24 h (NZ + Dox). The extracellular release of ATP was measured by a 
chemiluminescence-based assay. Data are presented as means + SD (n = 3). Versus Ctrl: *p < 0.05; versus Dox: °p < 0.001. (B) Western 
blot analysis of HMGB1 in the cell supernatants. Red Ponceau staining was used to check the equal loading of proteins. The figure is 
representative of 3 experiments. (C) The extracellular release of HMGB1 was measured by ELISA. Data are presented as means + SD 
(n = 3). Versus Ctrl: *p < 0.005; versus Dox: °p < 0.001. (D) Surface calreticulin (CRT) was measured by flow cytometry in duplicate. The 
figure is representative of 3 experiments. Anti-isotype: incubation with non immune isotypic antibody, included as negative control. (E) Six 
weeks-old female BALB/c mice bearing 60 mm3 JC-luc tumors were randomly divided into the following groups (10 mice/group): 1) Ctrl 
group, treated with 0.1 mL saline solution i.v. at day 3, 9, 15; 2) Dox group, treated with 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 3) ZA 
group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14; 4) ZA + Dox group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14 followed by 
5 mg/kg doxorubicin i.v. at day 3, 9, 15; 5) NZ group, treated with 20 µg/mouse self-assembling ZA formulation i.v. at day 2, 8, 14; 6) 
NZ + Dox group, treated with 20 µg/mouse NZ i.v. at day 2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at day 3, 9, 15. Sections of 
tumors from each group of animals were immunostained for CRT or CD11c, a marker of dendritic cells. Nuclei were counter-stained with 
hematoxylin. Bar = 10 µm (63× objective). The photographs are representative of sections from 5 (for CRT) or 10 (for CD11c) tumors/
group. The percentage of CRT-positive cells was determined by analyzing sections from 5 animals of each group (108–76 cells/field), 
using Photoshop program. The intensity of Ctrl group was considered 100%. The number of CD11c-positive cells/field was calculated by 
analyzing sections from 10 animals of each group (114–71 cells/field), using ImageJ software (http://imagej.nih.gov/ij/). Data are presented 
as means + SD. Versus Ctrl group: *p < 0.05; versus Dox group: °p < 0.001. 
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for tumor growth [38]. Of note, JC tumors were basally 
infiltrated of immunosuppressive Treg cells, as documented 
by the presence of Foxp3A+ cells (Figure 7D). ZA and 
doxorubicin did not modify such infiltrate, which was 
instead significantly reduced by NZ (Figure 7D). An active 
immune system was essential to mediate the anti-tumor 
effect of NZ and to fully rescue doxorubicin’s activity: 
indeed NZ, alone or in combination with doxorubicin, 
reduced JC tumor growth implanted also in NOD SCID 
mice (Supplementary Figure 7), but the anti-tumor activity 
of the combination “NZ plus doxorubicin” was significantly 
stronger in immunocompetent (Figure 2C) than in 
immunodeficient (Supplementary Figure 7) animals. 
DISCUSSION
In this work we show that NZ restores the sensitivity 
to doxorubicin in resistant breast tumors, re-inducing 
both the “direct” cytotoxic effects – i.e. reducing cell 
viability and inducing a necro-apoptotic cell death – and 
the “indirect” effects – i.e. restoring the doxorubicin-
induced immunogenic death – exerted by anthracyclines in 
responsive tumors.
NZ produced a significant chemosensitization 
in breast cancer cell lines that differ for the expression 
of estrogen receptor, progesterone receptor and human 
epidermal growth factor receptor 2 (Her2) [39]. Worthy of 
note, NZ exerted strong chemosensitizing effects in triple 
negative breast cancer cells such as MDA-MB-231 cells. 
This result is important in a translational perspective since 
the first-line therapy in triple negative breast cancers is 
chemotherapy, which achieves poor results for the intrinsic 
chemoresistance of these tumors [40]. Moreover, the 
chemosensitizing effects of NZ were not species-specific, 
since they were detected in both human and murine 
resistant cells. 
To validate the efficacy in vivo and investigate 
the molecular mechanisms of the NZ-induced 
chemosensitization, we focused on the JC model, which 
was the most chemoresistant cell line in vitro and was 
syngeneic with BALB/c mice [34]. This feature allowed 
us to set up a model of chemoresistant tumor implanted in 
immunocompetent animals and to examine the effects of NZ 
on both tumor and host immune system. 
Interestingly, whereas ZA did not reduce the tumor 
growth, NZ exerted a detectable anti-proliferative effect 
even when used alone. This result, which is in keeping 
with previous findings [30, 32], can be explained by 
the use of NPs that allows a higher delivery of the 
aminobisphosphonate within the tumor, compared to free 
ZA [28–33]. 
By reducing the Ras/ERK1/2 activity, NZ lowered 
the ERK1/2-dependent phosphorylation and activation 
of HIF-1α, which was constitutively translocated into the 
nucleus in JC cells even under normoxia, as it occurs in 
many chemoresistant cells [26]. Several HIF-1α target 
genes support cell proliferation and glucose metabolism 
through the glycolytic pathway [41]. In accord with these 
experimental evidences, NZ reduced proliferation, down-
regulated the expression levels of glycolytic genes and 
decreased the glucose flux through glycolysis and TCA 
cycle in our model. In parallel, by reducing the supply of 
isoprenoid moieties necessary for the electron transporter 
ubiquinone, it reduced the mitochondrial respiratory chain 
activity. This global impairment of the energy metabolism 
determined lower production of ATP and increased ROS 
levels, which damaged mitochondria and induced a 
mitochondria-dependent apoptosis. The simultaneous 
activation of glycolysis and oxidative phosphorylation is a 
typical feature of chemoresistant cells [42], which require 
huge amounts of ATP to support the ABC transporters 
activity. On the other hand, chemoresistant cells are more 
susceptible to the ATP depletion and to the ROS-induced 
damage than chemosensitive cells [43]. NZ, by decreasing 
ATP supply and increasing ROS levels, hits two “Achille’s 
heels” of chemoresistant cells. This mechanism can 
explain the anti-proliferative effect of NZ alone against 
chemoresistant breast tumors.
More importantly, NZ restored the anti-tumor efficacy 
of doxorubicin in JC tumors, which were fully refractory 
to the drug. In line with the in vitro data, the combination 
of NZ and doxorubicin was more effective than the 
combination of ZA and doxorubicin. Since Pgp is a target 
gene of HIF-1α [41], the circumvention of doxorubicin 
resistance in NZ-treated animals was likely due to the 
down-regulation of the HIF-1α-mediated transcription of 
Pgp. It has been reported that doxorubicin activates HIF-1α 
by decreasing the intracellular availability of iron [44]: this 
finding is in accord with our scenario, where doxorubicin 
increased the transcriptional activity of HIF-1α in a Ras/
ERK1/2-independent way. Although the intra-tumor 
concentration of doxorubicin in JC tumors is very low [45], 
such concentration was sufficient to increase HIF-1α and 
up-regulate Pgp levels, glycolytic genes levels, glucose 
uptake and metabolism through glycolysis and TCA cycle. 
This metabolic signature, which provides JC tumors with 
ATP and can maintain the ATP-dependent activity of Pgp, 
was abrogated by NZ. 
The low concentration of doxorubicin within 
JC tumors, however, was not sufficient to impair the 
mitochondrial respiratory chain and increase the ROS 
production from Complex I, two events that contribute to 
the doxorubicin cytotoxicity in drug-sensitive cells [46, 47], 
but not in drug-resistant ones [45]. NZ, which increased the 
intracellular retention of doxorubicin in JC cells, restored 
also these “mitochondrial” effects of the drug. Moreover, 
NZ alone impaired the mitochondrial energy metabolism. 
We might speculate that in tumors exposed to NZ and 
doxorubicin the effects of NZ on mitochondria functions 
are additive to the effects of doxorubicin: the two drugs 
strongly reduced the electron flux and ATP synthesis, 
increased ROS levels and mitochondrial depolarization, 
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Figure 7: NZ counteracts the tumor-induced immunosuppressive microenvironment. Six weeks-old female BALB/c mice 
bearing 60 mm3 JC-luc tumors were randomly divided into the following groups (10 mice/group): 1) Ctrl group, treated with 0.1 mL saline 
solution i.v. at day 3, 9, 15; 2) Dox group, treated with 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 3) ZA group, treated with 20 µg/mouse 
ZA i.v. at day 2, 8, 14; 4) ZA + Dox group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at day 
3, 9, 15; 5) NZ group, treated with 20 µg/mouse self-assembling ZA formulation i.v. at day 2, 8, 14; 6) NZ + Dox group, treated with 
20 µg/mouse NZ i.v. at day 2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at day 3, 9, 15. (A) Tumor extracts were subjected to the Western 
blot analysis for phospho(Tyr705)-STAT3, phospho(Ser727)-STAT3, total STAT3. The actin expression was used as control of equal protein 
loading. The figure is representative of 4 tumors per each group. (B) IDO mRNA levels were detected in each tumor extract (n = 10/group) 
by qRT-PCR. Data are presented as means + SD. Versus Ctrl group: *p < 0.01; versus Dox group: °p < 0.01. (C) The release of kynurenine 
in the tumor supernatants was measured spectrophotometrically (n = 10/group). Data are presented as means + SD. Versus untreated Ctrl 
group: *p < 0.02; versus Dox group: °p < 0.02. (D) Sections of tumors from each group of animals were immunostained for Foxp3A, a 
marker of Treg cells. Nuclei were counter-stained with hematoxylin. Bar = 10 µm (63× objective). The photographs are representative 
of sections from 10 tumors/group. The number of Foxp3A-positive cells/field was calculated by analyzing sections from 10 animals of 
each group (111–75 cells/field), using ImageJ software (http://imagej.nih.gov/ij/). Data are presented as means + SD. Versus Ctrl group: 
*p < 0.02; versus Dox group: °p < 0.005. 
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activated the cytochrome c/caspase 9/caspase 3-dependent 
pro-apoptotic axis. 
The effects of ZA on HIF-1α transcriptional activity, 
glucose metabolism and mitochondrial functions were lower 
than those elicited by NZ. As noted earlier, the lower intra-
tumor uptake of free ZA compared to NZ [28–32] limits 
the ability of the former to reduce the synthesis of FPP and 
ubiquinone, to inhibit the Ras/ERK1/2/HIF-1α/Pgp axis, to 
impair the energy metabolism, to fully restore doxorubicin’s 
efficacy in vivo.
In partial contrast with our work, the treatment with 
ZA administered before doxorubicin has not improved the 
efficacy of the anthracycline in human MDA-MB-436 cells 
implanted in nude mice [48]. This model, however, differs 
from the one used in our work for several reasons. First, 
the use of free ZA instead of NZ reduces the antitumor 
effects of the aminobisphosphonate, as demonstrated in 
other tumor models [30, 32]. Second, ZA and doxorubicin 
target both tumor cells and tumor-associated immune cells 
[13, 49, 50]: the use of immunodeficient mice did not allow 
to investigate the effects of ZA and doxorubicin on the host 
immune system. Our comparison between the anti-tumor 
effect of NZ in immunocompetent and immunodeficient 
mice suggested that, although NZ was effective also in 
immunodeficient animals, in line with previous observations 
[30–33], it achieved the maximal efficacy in animals with an 
active immune system. These results suggest that part of the 
anti-tumor effects of NZ was mediated by the activation of 
the host immune system against the tumor. 
Indeed, we found that NZ restored the antitumor 
efficacy of doxorubicin also by rescuing its pro-
immunogenic effects, as revealed by the increased 
extracellular release of ATP and HMGB1, and by the 
increased amount of CRT on the plasma membrane. 
The concurrent presence of these three events is widely 
recognized as indexes of immunogenic cell death [37]. In 
our model, the release of ATP and HMGB1 elicited by NZ 
started later than the triggering of apoptosis: these findings 
led to hypothesize that the apoptotic process induced by 
NZ primes cells for a more severe damage, leading to 
the release of ATP and HMGB1. We cannot exclude that 
these molecules are released passively as a consequence 
of the necro-apoptotic cell death; however, since they are 
paralleled by the exposure of CRT on cell surface, they 
can suggest a simultaneous induction of immunogenic cell 
death.
The exposure of CRT on the cell surface coupled 
with the reduction of Pgp levels, two events that 
occurred in JC tumors treated with NZ and doxorubicin, 
are necessary to trigger the tumor cell phagocytosis 
by local DCs [15, 26]. The increased amount of DCs 
infiltrating JC tumors treated with NZ and doxorubicin 
suggests an increased recruitment of local DCs. Although 
the presence of DCs within breast tumors has been 
associated with either anti-tumor or pro-tumor effects, 
the presence of DCs activated by the release of HMGB1 
has been unequivocally correlated with the recruitment 
of T-lymphocytes recognizing tumor-associated antigens 
[21]. An immunotherapy based on the only boosting of 
DCs, however, is ineffective in breast cancer and requires 
the integration with chemotherapy and/or therapeutic tools 
that inhibit immunosuppressive lymphocytes [23]. 
According to our data, NZ can be an excellent 
immunoadjuvant agent: indeed, besides recruiting local 
DCs, it lowered the production of the immunosuppressive 
metabolite kynurenine by the resistant tumors. The 
expression of IDO, the main enzyme producing 
kynurenine in resistant cancer cells [17], is controlled by 
the transcriptional factor STAT3, which is active when 
phosphorylated on tyrosine 705 and serine 727 [51, 52]. 
In resistant malignant pleural mesothelioma cells, the Ras/
ERK1/2 axis promotes the phosphorylation of STAT3 on 
serine 727 and increases the transcription of IDO; this event 
is prevented by ZA and reduces the ex vivo expansion of 
immunosuppressive Treg cells [16]. A similar mechanism 
occurred in JC tumors, where ZA and in particular NZ 
reduced the phosphorylation of STAT3 on serine 727. The 
slight reduction of phospho(Ser727)STAT3 elicited by 
ZA, however, was not sufficient to produce any change 
in kynurenine synthesis. By contrast, the strong inhibition 
of STAT3 phosphorylation induced by NZ decreased the 
transcription of IDO mRNA, the release of kynurenine in 
the tumor supernatant and the infiltration of Treg cells. 
The only decrease in Treg cells is sufficient to 
reverse the immunotolerant microenvironment created 
by solid tumors, also in the absence of changes in other 
classes of B- and T-lymphocytes [38, 53]. When effective, 
anthracycline-based regimens reduce the intra-tumor 
Foxp3A+ cells without changing the amount of CD8+ 
T-lymphocytes [54]. Interestingly, in a large phase III 
trial the decrease of intra-tumor Foxp3A+ cells has been 
predictive of anthracyclines efficacy in patients with breast 
cancer [55]. In JC resistant tumors, doxorubicin did not 
modify the percentage of intra-tumor Foxp3A+ Treg cells. 
This was likely an additional mechanism of doxorubicin 
resistance: of note, this feature was counteracted by the 
pre-treatment with NZ. 
In conclusion our work suggests that NZ is a multi-
target chemo-immunosensitizing agent, acting on both 
tumor cell and tumor microenvironment. On the one hand, 
it exerts cytotoxic effects against breast tumors refractory 
to doxorubicin when used alone, by impairing the tumor 
energy metabolism and reducing the tumor-induced 
immunosuppression. On the other hand, NZ overcomes the 
resistance to doxorubicin by at least two mechanisms: 1) it 
increases the intracellular retention of the drug, enhancing 
the direct cytotoxicity of doxorubicin on tumor cells; 2) it 
restores the doxorubicin-induced immunogenic cell death, 
re-establishing an anti-tumor immune microenvironment 
(Figure 8). We propose the use of NZ as an adjuvant tool 
in chemo-immunotherapy protocols for the treatment of 
anthracycline-refractory breast tumors. 
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Figure 8: Effects of NZ on tumor cells and tumor-associated immune microenvironment. By inhibiting the farnesyl 
pyrophosphate synthase (FPPS), self-assembling zoledronic acid formulation (NZ) reduces the isoprenoids supply. This event implies: 
1) lower activity of Ras/ERK1/2/HIF-1α axis, lower HIF-1α-dependent transcription of P-glycoprotein (Pgp) and lower production of 
ATP via HIF-1α-dependent anaerobic energy metabolism; 2) reduced amount of the electron carrier ubiquinone (U), which decreases 
the mitochondrial aerobic energy metabolism and further diminishes the ATP supply for Pgp; 3) reduced activity of Ras/ERK1/2/STAT3 
axis, lower expression of indoleamine 2,3 dioxygenase (IDO) and lower production of the immunosuppressive metabolite kynureine (K) 
that is required for the expansion of the tumor-tolerant T-regulatory (Treg) cells. The impairment in tumor energy metabolism and the 
reduction of Treg may explain the anti-tumor effect of NZ. When co-administered with doxorubicin (D), NZ reduces the drug efflux owing 
to the lower expression of Pgp; in parallel, it increases the doxorubicin-mediated exposure of calreticulin (CRT) that activates the tumor 
cell phagocytosis by local dendritic cells (DC). Hence, NZ induces chemosensitization and immunosensitization. Dotted lines: pathways 
inhibited by NZ; continuous lines: pathways activated by NZ. 
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MATERIALS AND METHODS
Ethical statement
Investigation has been conducted in accordance with 
the ethical standards, the Declaration of Helsinki, national 
and international guidelines, and has been approved by the 
Bio-Ethical Committee of the University of Turin, Italy.
Chemicals
Fetal bovine serum and culture medium were from 
Invitrogen Life Technologies (Carlsbad, CA). Plasticware 
for cell cultures was from Falcon (Becton Dickinson, 
Franklin Lakes, NJ). ZA was a gift from Novartis (Basel, 
Switzerland). Electrophoresis reagents were obtained from 
Bio-Rad Laboratories (Hercules, CA). The protein content 
in cell lysates and tumor homogenates was assessed with 
the BCA kit from Sigma Chemical Co. (St. Louis, MO). 
Unless otherwise specified, all the other reagents were 
purchased from Sigma Chemical Co.
Preparation and characterization of NZ
Self-assembling NPs encapsulating ZA were prepared 
as previously reported [28]. Briefly, an aqueous solution of 
18 mmol/L CaCl2 was added, dropwise and under magnetic 
stirring, to an aqueous solution of 10.8 mmol/L Na2HPO4. 
The resulting suspension (termed CaPNPs) was filtered 
through a 0.22 µm polycarbonate filter (MF-Millipore, 
Microglass Heim, Italy) and stored at 4°C before use. ZA 
was then complexed with CaPNPs (to obtain CaPZNPs), 
at a volume ratio of 50:1, with a final ZA concentration of 
50 mg/mL. Cationic liposomes (N-[1-(2,3-dioleoyloxy)
propyl]-N,N,N-trimethylammonium chloride/cholesterol/ 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino 
(polyethylene glycol)-2000] at a ratio of 1:1:0.5) were 
prepared by hydration of a thin lipid film followed by 
extrusion. The lipid mixture dissolved in chloroform/
methanol (2:1 v/v) was added to a 50 mL round-bottom 
flask and the solvent was removed under reduced pressure 
by a rotary evaporator (Laborota 4010 digital, Heidolph, 
Schwabach, Germany) in nitrogen atmosphere. The resulting 
lipid film was hydrated with 1 mL of 0.22 µm-filtered 
distilled water and the resulting suspension was gently 
mixed in the presence of glass beads followed by incubation 
at room temperature for 2 h. The liposome suspension 
was then extruded using a thermobarrel extruder system 
(Northern Lipids Inc., Vancouver, BC, Canada) passing 
repeatedly the suspension under nitrogen atmosphere 
through polycarbonate membranes with decreasing pore 
sizes from 400 to 100 nm (Nucleopore Track Membrane 
25 mm, Whatman, Brentford, UK). The liposomes were 
stored at 4°C. Each formulation was prepared in triplicate. 
Finally, equal volumes of suspensions of the liposomes and 
CaPZNPs, respectively, were mixed in a glass tube and the 
resulting dispersion was maintained at room temperature 
for 10 min. NPs without ZA were also prepared similarly, 
starting from CaPNPs and cationic liposomes. Each 
formulation was prepared in triplicate.
The mean diameter of stealth liposomes and 
CaPZNPs were determined at 20°C by photon correlation 
spectroscopy (N5, Beckman Coulter, Miami, FL). Each 
sample was diluted in deionizer/filtered water and analyzed 
with detector at 90° angle. Polydispersity index (P.I.) was 
used as measure of the particle size distribution. For each 
batch, the mean diameter and size distribution were the 
mean of three measures. For each formulation, the mean 
diameter and P.I. were calculated as the mean of three 
different batches. The zeta potential (ζ) of the NP surface 
was measured in water by means of a Zetasizer Nano Z 
(Malvern, UK). Data of ζ were collected as the average 
of 20 measurements. To measure the ZA encapsulation 
efficacy, 1 mL of NP dispersion was ultra-centrifuged 
(Optima Max E, Beckman Coulter) at 80,000 × g at 4°C 
for 40 min. Supernatants were carefully removed and ZA 
concentration was determined by high pressure liquid 
chromatography. The ZA encapsulation efficiency was 
calculated as [(TSZA – ASZA)/TSZA] × 100, where TSZA is 
the theoretical ZA in the supernatant and ASZA is the actual 
ZA concentration in the supernatant. 
Cells
Human non-transformed breast epithelial MCF10A 
cells, human breast cancer MCF7, SKBR3, T74D, MDA-
MB-231 cells and murine mammary cancer JC cells were 
purchased from ATCC (Manassas, VA). Murine mammary 
cancer TUBO cells were a kind gift of Prof. Federica 
Cavallo, Department of Molecular Biotechnology and 
Health Sciences, University of Turin, Italy. Cells were 
maintained in medium supplemented with 10% v/v fetal 
bovine serum, 1% v/v penicillin-streptomycin, 1% v/v 
L-glutamine. 2 × 105 JC cells were stably transfected 
with 2 μg of pGL4.51[luc2/CMV/Neo] vector (Promega 
Corporation, Madison, WI), then selected in culture medium 
containing 1 μg/mL neomycin to generate the stably 
luciferase-expressing JC-luc clone.
Western blot analysis
Cells were lysed in MLB buffer (125 mmol/L Tris-
HCl, 750 mmol/L NaCl, 1% v/v NP40, 10% v/v glycerol, 
50 mmol/L MgCl2, 5 mmol/L EDTA, 25 mmol/L NaF, 
1 mmol/L NaVO4, 10 μg/mL leupeptin, 10 μg/mL pepstatin, 
10 μg/mL aprotinin, 1 mmol/L phenylmethylsulfonyl 
fluoride, pH 7.5), sonicated and centrifuged at 13,000 × g 
for 10 min at 4°C. Tumors were frozen at −80°C for 24 h, 
then homogenized in MLB buffer and treated as reported 
above. 20 μg of proteins from cell lysates or tumor 
homogenates were subjected to Western blotting and probed 
with the following antibodies: anti-Pgp (BD Biosciences, 
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San Josè, CA), anti-MRP1 (Abcam, Cambridge, UK), 
anti-Ras (Millipore, Billerica, MA), anti-phospho(Thr202/
Tyr204, Thr185/Tyr187)-ERK1/2 (Millipore), anti-ERK 1/2 
(Millipore), anti-phospho(Tyr705)-STAT3 (Cell Signaling 
Technology, Danvers, MA), anti-phospho(Ser727)-
STAT3 (Cell Signaling Technology), anti-STAT3 (Thermo 
Scientific, Rockford, IL). The proteins were detected by 
enhanced chemiluminescence (Bio-Rad Laboratories). 
To evaluate the activity of Ras, the Ras GTP-
bound fraction, taken as an index of the active protein, 
was measured in a pull-down assay using Raf-1-GST 
fusion protein-agarose beads-conjugates (Millipore) and 
then probing the immuno-precipitated samples with an 
anti-Ras (Millipore) antibody. Nuclei-cytosol separation 
was obtained with the Nuclear Extract Kit (Active Motif, 
Rixensart, Belgium). To assess HIF-1α phosphorylation, the 
cytosolic lysate was immunoprecipitated with a polyclonal 
anti-HIF-1α antibody (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA), then resolved by SDS-PAGE and probed 
with a biotin-conjugated anti-phosphoserine antibody 
(Sigma Chemical Co.), followed by polymeric streptavidin-
horseradish peroxidase-conjugates (Sigma Chemical Co.). 
10 μg nuclear proteins were resolved by SDS-PAGE and 
probed with an anti-HIF-1α antibody (BD Biosciences), 
to measure the amount of protein translocated into the 
nucleus. The amount of cytochrome c in the cytosolic and 
mitochondrial extracts was measured as described in [56], 
using an anti-cytochrome c antibody (BD Biosciences). 
The equal protein loading in whole cell lysates, nuclear 
and mitochondrial extracts was checked by using anti-actin 
(Sigma Chemical Co.), anti-TATA-box binding protein 
(TBP; Santa Cruz Biotechnology Inc.), anti-porin (Abcam) 
antibodies, respectively. 
Intracellular doxorubicin accumulation
Cells were incubated for 3 h with 5 µmol/L 
doxorubicin, then washed twice in PBS, detached with 
trypsin-EDTA, centrifuged at 1,300 × g for 2 min, sonicated 
and re-suspended in 0.5 mL ethanol/0.3 N HCl. The amount 
of doxorubicin was measured spectrofluorimetrically, using 
a Synergy HT Multi-Detection Microplate Reader (Bio-
Tek Instruments, Winooski, VT). Excitation and emission 
wavelengths were 475 nm and 553 nm. Fluorescence was 
converted into nmoles/mg cell proteins, using a calibration 
curve previously set.
Cell viability
To determine IC50, 5 × 10
5 cells were incubated 
in the absence or presence of 1 µmol/L ZA or NZ for 
72 h, with increasing concentrations of doxorubicin (from 
1 nmol/L to 1 mmol/L) in the last 48 h. IC50 was considered 
the concentration of doxorubicin that kills 50% cells. Viable 
cells were quantified by the neutral red staining method, as 
previously reported [57]: at the end of the treatment period, 
cells were incubated for 1 h at 37°C in culture medium 
containing 70 μg/mL of neutral red solution (Sigma 
Chemical Co.), then washed three times with PBS and 
rinsed with stop buffer (32 mmol/L trisodium citrate, 50% 
v/v methanol, pH 6). The absorbance at 540 nm was read 
using a Synergy HT Multi-Detection Microplate Reader 
(Bio-Tek Instruments). The absorbance of untreated cells 
was considered as 100% viability; the results were expressed 
as percentage of viable cells versus untreated cells. 
Cytotoxicity assays
The release of HMGB1 in the cell culture 
supernatant was measured using the High Mobility Group 
Protein 1 ELISA kit (Cloud-Clone Corp., Houston, Texas), 
following the manufacturer’s instructions. Results were 
expressed in pg/mg cell proteins, according to a titration 
curve previously prepared. In parallel, 20 μL of the cell 
culture medium were resolved by SDS-PAGE and probed 
with an anti-HMGB1 antibody (Sigma Chemical Co.). 
Blots were pre-stained with Red Ponceau, to check the 
equal loading of proteins.
In vivo assays
1 × 106 JC or JC-luc cells, mixed with 100 µL 
Matrigel, were injected subcutaneously in 6 weeks-old 
immunocompetent or NOD SCID female BALB/c mice, 
housed (5 per cages) under 12 h light/dark cycle, with 
food and drinking provided ad libitum. Palpable tumors 
developed 2-3 weeks after injection. The tumor growth was 
measured daily by caliper and was calculated according to 
the equation (L × W2)/2, where L = tumor length; W = tumor 
width. When the tumor reached the volume of 60 mm3, the 
mice were randomized into 6 groups: 1) Ctrl group, treated 
with 0.1 mL saline solution i.v. at day 3, 9, 15; 2) Dox group, 
treated with 5 mg/kg doxorubicin i.v. at day 3, 9, 15; 3) ZA 
group, treated with 20 µg/mouse ZA i.v. at day 2, 8, 14; 
4) ZA + Dox group, treated with 20 µg/mouse ZA i.v. 
at day 2, 8, 14 followed by 5 mg/kg doxorubicin i.v. at 
day 3, 9, 15; 5) NZ group, treated with 20 µg/mouse 
NZ i.v. at day 2, 8, 14; 6) NZ + Dox group, treated 
with 20 µg/mouse NZ i.v. at day 2, 8, 14 followed 
by 5 mg/kg doxorubicin i.v. at day 3, 9, 15. In vivo 
bioluminescence imaging was performed at day 0, 6, 12, 
18 after randomization, with a Xenogen IVIS Spectrum 
(PerkinElmer, Waltham, MA). Tumor volumes were 
monitored daily and animals were euthanized by injecting 
i.m. zolazepam (0.2 mL/kg) and xylazine (16 mg/kg) 
at day 21 after randomization. The hematochemical 
parameters LDH, AST, ALT, AP, CPK, creatinine were 
measured on 0.5 mL of blood collected immediately after 
mice sacrifice, using commercially available kits from 
Beckman Coulter Inc. 
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Immunohistochemistry
Tumors were resected, photographed and fixed in 
4% v/v paraformaldehyde. The sections were stained with 
hematoxylin/eosin or immunostained for Ki67 (Millipore), 
Pgp (Millipore), CRT (Affinity Bioreagents, Golden, 
CO), CD11c (BD Biosciences), CD19 (BD Biosciences), 
CD4 (Abcam), CD8 (Abcam), Foxp3A (eBioscience, 
San Diego, CA), followed by a peroxidase-conjugated 
secondary antibody (Dako, Glostrup, Denmark). Nuclei 
were counterstained with hematoxylin. 
HIF-1α activity
The activity of HIF-1α was assessed on 10 μg 
proteins from nuclear extracts with the TransAM™ HIF-1 
Transcription Factor Assay Kit (Active Motif). Data 
were expressed as mU absorbance/mg nuclear proteins. 
For each set of experiments, a blank (with bis-distilled 
water), a negative control (with mutated oligonucleotide) 
and a competition assay (with 10 pmoles of the wild 
type oligonucleotide and 100 pmoles of the mutated 
oligonucleotide incubated with the nuclear extracts of 
JC cells grown at 3% O2 for 24 h), were included. In 
hypoxic conditions, the activity of HIF-1α was 307.23 ± 
12.81 mU/mg nuclear proteins; in the competition assay, the 
corresponding HIF-1α activity was reduced to 27.75 ± 5.71 
mU/mg nuclear proteins (n = 3; p < 0.001).
Quantitative real time PCR (qRT-PCR)
Total RNA was extracted by phenol/chloroform 
method; 1 µg RNA was reverse-transcribed using the 
iScript Reverse Transcription Supermix kit (Bio-Rad 
Laboratories), according to the manufacturer’s instruction. 
25 ng cDNA were amplified with 10 µL IQTM SYBR Green 
Supermix (Bio-Rad Laboratories), using 400 nmol/L of 
forward and reverse primers. Primers sequence is listed in 
the Supplementary Table 1. RT-PCR was carried out with 
a iQTM5 cycler (Bio-Rad Laboratories). Cycling conditions 
were: 30 s at 95°C, followed by 40 cycles of denaturation 
(15 s at 95°C), annealing/extension (30 s at 60°C). The 
same cDNA preparation was used to quantify the genes of 
interest and the housekeeping gene S14, used to normalize 
gene expression. The relative quantitation of each sample 
was performed using the Gene Expression Quantitation 
software (Bio-Rad Laboratories). Results were expressed 
in arbitrary units. For each gene, the expression in 
untreated cells was considered “1”. 
Glucose uptake and metabolism
The uptake of glucose was measured as described 
earlier [58], by radiolabeling cells with 0.3 µCi/mL 
2-deoxy-D-[3H]-glucose (7.5 Ci/mmol, PerkinElmer). The 
uptake values were corrected for the non carrier-mediated 
transport by measuring the uptake in the presence of 
10 µmol/L cytochalasin B, an inhibitor of the facilitated 
glucose transport: such value was always < 10% of the total 
uptake. The results were expressed as pmoles 2-deoxy-D-
[3H]-glucose/mg cell proteins. The glucose flux through 
glycolysis and TCA cycle was measured by radiolabeling 
cells with 2 μCi/mL [6–14C]-glucose (55 mCi/mmol; 
PerkinElmer). Cell suspensions were incubated for 1 h at 
37°C in a closed experimental system to trap the 14CO2 
developed from [14C]-glucose, and the reaction was stopped 
by injecting 0.5 mL of 0.8 N HClO4. The amount of glucose 
transformed into CO2 through the glycolysis and the TCA 
cycle was calculated as described [59] and expressed as 
pmoles CO2/h/mg cell proteins.
Mitochondrial respiratory chain assays
Mitochondria were extracted as described earlier 
[56]. A 50 μL aliquot was sonicated and used for the 
measurement of protein content or Western blotting; the 
remaining part was stored at −80°C until the use. To confirm 
the presence of mitochondrial proteins in the extracts, 
10 μg of each sonicated sample was subjected to SDS-
PAGE and probed with an anti-porin antibody (Abcam; data 
not shown). The electron flux from Complex I to Complex 
III was measured on 10 μg of non-sonicated mitochondrial 
extracts, re-suspended in 150 µL buffer A (5 mmol/L 
KH2PO4, 5 mmol/L MgCl2, 5% w/v bovine serum albumin). 
Then 75 µL buffer B (25% w/v saponin, 50 mmol/L 
KH2PO4, 5 mmol/L MgCl2, 5% w/v bovine serum albumin, 
0.12 mmol/L cytochrome c-oxidized form, 0.2 mmol/L 
NaN3) were added for 5 min at room temperature. Each 
sample was incubated in the absence or presence of the 
Complex I inhibitor rotenone (50 µmol/L), to measure the 
ubiquinone-independent and the ubiquinone-dependent 
electron flux, respectively. The reaction was started with 
0.15 mmol/L NADH and was followed for 5 min, using a 
Synergy HT Multi-Detection Microplate Reader (Bio-Tek 
Instruments). Results were expressed as nmoles reduced 
cytochrome c/min/mg mitochondrial proteins. 
ATP measurement
The amount of ATP was measured on 20 μg of 
mitochondrial proteins or on 100 μL of cell supernatants 
with the ATP Bioluminescent Assay Kit (FL-AA, Sigma 
Chemical Co.), using a Synergy HT Multi-Detection 
Microplate Reader (Bio-Tek Instruments). ATP was 
quantified as arbitrary light units; data were converted 
into nmoles/mg mitochondrial or cellular proteins, using a 
calibration curve previously set.
ROS measurement
Mitochondria were extracted, re-suspended in a 
final volume of 0.5 mL PBS, incubated for 30 min at 37°C 
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with the fluorescent probe 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydro-fluorescein diacetate-acetoxymethyl ester 
(5 μmol/L; DCFDA-AM), centrifuged at 13,000 × g for 
5 min and re-suspended in 0.5 mL PBS. The fluorescence 
of each sample, taken as index of ROS level, was read 
at 492 nm (excitation) and 517 nm (emission), using a 
Synergy HT Multi-Detection Microplate Reader (Bio-Tek 
Instruments). The results were expressed as nmoles/mg 
mitochondrial proteins.
Mitochondrial electric potential (Δψ) 
measurement
1 × 106 cells re-suspended in 0.5 mL PBS were 
incubated for 30 min at 37°C with the fluorescent probe JC-1 
(2 µmol/L; Biotium Inc., Hayward, CA), then centrifuged at 
13,000 × g for 5 min and re-suspended in 0.5 mL PBS. The 
fluorescence of each sample was read using a Synergy HT 
Multi-Detection Microplate Reader (Bio-Tek Instruments): 
the red fluorescence, index of polarized mitochondria, was 
detected at 550 nm (excitation) and 600 nm (emission); 
the green fluorescence, index of depolarized and damaged 
mitochondria, was detected at 485 nm (excitation) and 
535 nm (emission). The fluorescence units were used to 
calculate the percentage of green-fluorescent mitochondria 
versus red-fluorescent mitochondria.
Caspases activity
The activity of caspase 9 and caspase 3 was measured 
as reported in [60]. Cells were lysed in 0.5 mL of caspase 
lysis buffer (20 mmol/L Hepes/KOH, 10 mmol/L KCl, 
1.5 mmol/L MgCl2, 1 mmol/L EGTA, 1 mmol/L EDTA, 
1 mmol/L dithiothreitol, 1 mmol/L phenylmethylsulfonyl 
fluoride, 10 µg/mL leupeptin, pH 7.5). 20 μg cell lysates 
were incubated for 1 h at 37°C with 20 µmol/L of the 
fluorogenic substrate of caspase 9 Ac-Leu-Glu-His-Asp-
7-amino-4-methylcoumarin (LEHD-AMC) or fluorogenic 
substrate of caspase 3 Ac-Asp-Glu-Val-Asp-7-amino-4-
methylcoumarin (DEVD-AMC), in 0.25 mL caspase assay 
buffer (25 mmol/L Hepes, 0.1 % w/v 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate, 10% w/v sucrose, 
10 mmol/L dithiothreitol, 0.01% w/v egg albumin, 
pH 7.5). The reaction was stopped by adding 0.75 mL ice-
cold 0.1% w/v trichloroacetic acid and the fluorescence of 
AMC fragment released by active caspases was read using 
a Synergy HT Multi-Detection Microplate Reader (Bio-Tek 
Instruments). Excitation and emission wavelengths were 380 
and 460 nm, respectively. Fluorescence was converted in 
nmoles/mg cell proteins, using a calibration curve prepared 
previously with standard solutions of AMC.
Flow cytometry analysis
1 × 106 cells, rinsed and fixed with 2% w/v 
paraformaldehyde for 2 min, were washed three times 
with PBS and stained with an anti-CRT antibody (Affinity 
Bioreagents) for 1 h on ice. After washing, samples were 
incubated with an AlexaFluor 488-conjugated secondary 
antibody (Millipore) for 30 min and re-washed. Samples 
were analyzed with a Guava easyCyte flow cytometer 
(Millipore). For each analysis 10,000 events were collected. 
Control experiments included incubation with non immune 
isotypic antibody followed by the secondary antibody. 
The results were analyzed with the easyCyte software 
(Millipore).
Kynurenine production
Tumor pieces were collected immediately after mice 
sacrifice and maintained for 24 h in culture medium, then 
200 μL of the supernatants were used to measure the levels 
of kynurenine, taken as index of IDO activity, as previously 
detailed [17]. Supernatants were added to 100 μL of 30% 
w/v trichloroacetic acid and incubated for 30 min at 50°C 
to hydrolyze N-formylkynurenine to kynurenine. After 
centrifugation at 10,000 × g for 10 min, 100 μL of the 
supernatant were transferred into a 96-well plate, mixed 
with 100 μL of 2% w/v p-dimethylamino benzaldehyde in 
99.8% v/v acetic acid, and incubated for 10 min at room 
temperature. Kynurenine was detected by measuring the 
absorbance at 490 nm, using a Synergy HT Multi-Detection 
Microplate Reader (Bio-Tek Instruments). The absorbance 
of the culture medium alone was considered as a blank and 
was subtracted from the values obtained in the presence of 
the cells. The results were expressed as nmol kynurenine/mg 
cell proteins, according to a titration curve previously set.
FPP and ubiquinone synthesis
Cells were labeled with 1 μCi/mL [3H]-acetate 
(3600 mCi/mmol; Amersham Bioscience, Little Chalfont, 
UK). The synthesis of radiolabeled FPP and ubiquinone 
was measured as described in [61]. Results were expressed 
as pmoles [3H]-FPP or [3H]-ubiquinone/mg cell proteins, 
according to the relative calibration curve.
Statistical analysis
All data in text and figures are provided as 
means ± SD. The results were analyzed by a one-way 
analysis of variance (ANOVA) and Tukey’s test. p < 0.05 
was considered significant.
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